ERBB2 and breast carcinoma: One study revealed that entinostat promoted lapatinib efficacy via inhibition of AKT phosphorylation, activation of FOXO3 transcription, leading to elevation of Bim1 expression in breast cancer cells with HER2 overexpression (53).